A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma Read more
A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma Read more
A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma Read more
Outcomes Of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Patients: Real World Experience In Lymphoma Patients Read more
Outcomes And Prognostic Factors Of Patients Diagnosed With High-Grade B-Cell Lymphoma, Not Otherwise Specified: A Multi-Institutional Retrospective Study Read more
An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) Read more
A Global Randomized Multicenter Phase 3 Trial Of JCAR017 Compared To Standard Of Care In Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM). Read more
Phase I/II Of Nivolumab And A(B)VD In The Front-Line Setting For High Risk Hodgkin Lymphoma Read more
